Pakistan Pharmaceuticals: 2QCY25 results shows divergent trend – By Insight Research
Aug 28 2025
Insight Securities
- The 2QCY25 results for pharmaceutical sector have started to come in, reflecting a mixed performance, with some companies posting growth while others underperformed. The sector underwent a major shift last year when the government deregulated prices of non essential medicines. This policy change has driven a sharp rise in revenues and margins over the past four quarters, though the extent and timing of the impact varied across companies depending on their cost adjustments, seasonality, and product mix.
- In 2QCY25, HALEON, HPL & ABOT recorded topline growth of ~16%, 15% & 10% QoQ, respectively. The increase is mainly attributable to better product availability post de regulation and addition of new products in the mix. Moreover, the gross margins for the above mentioned companies also witnessed decent improvement, where HALEON’s gross margin inch up by ~660/610bps YoY/QoQ in 2QCY25, while margins for ABOT, inch up by ~1140/180bps YoY/QoQ. For HPL, margins improved YoY by 300bps, however same is down by ~180bps QoQ, possibly due to depreciation of local currency against Euro. On the flip side, revenue for AGP, HINOON & GLAXO fell by ~22%, 12% & 6% QoQ. While margins for these companies recorded improvement both YoY/QoQ. The revenue contraction is attributable to procurement challenges arising from the Indo-Pak war and logistical disruptions.